Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai HeartCare Medical TechnologyHKSE:06609 -4.29%78 PE Ratio without NRI is 21.01 as of Aug. 29, 2026, which is 3% below its 10-year median of 21.61. GuruFocus rates HKSE:06609 with a GF Score™ of 78/100 and a GF Value™ of HK$54.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 456 Medical Devices & Instruments companies, Shanghai HeartCare Medical Technology ranks better than 55.04% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-08-29), Shanghai HeartCare Medical Technology's share price is HK$48.24.
Shanghai HeartCare Medical Technology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was HK$2.30. Therefore, Shanghai HeartCare Medical Technology's PE Ratio without NRI for today is 21.01.
During the past 7 years, Shanghai HeartCare Medical Technology's highest PE Ratio without NRI was 27.51. The lowest was 18.25. And the median was 21.61.
Shanghai HeartCare Medical Technology (HKSE:06609) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Shanghai HeartCare Medical Technology PE Ratio without NRI Related Terms
Shanghai HeartCare Medical Technology PE Ratio without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology PE Ratio without NRI Chart
HKSE:06609 vs ABT, SYK, MDT: PE Ratio without NRI Comparison
For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai HeartCare Medical Technology PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Shanghai HeartCare Medical Technology's PE Ratio without NRI falls into.
Shanghai HeartCare Medical Technology PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Shanghai HeartCare Medical Technology's Share Price of today is HK$48.24.
For company reported semi-annually, Shanghai HeartCare Medical Technology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Shanghai HeartCare Medical Technology (HKSE:06609) has a PE Ratio without NRI of 21.01 as of Aug. 29, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Shanghai HeartCare Medical Technology and its competitors. This is near median its historical median of 21.61. Over the past decade, Shanghai HeartCare Medical Technology's PE Ratio without NRI has ranged from 18.25 to 27.51. According to the industry distribution chart, Shanghai HeartCare Medical Technology ranks #205 out of 456 companies in the Medical Devices & Instruments industry, placing it in the top 45%.
Is Shanghai HeartCare Medical Technology's PE Ratio without NRI too high?
Shanghai HeartCare Medical Technology's current PE Ratio without NRI of 21.01 is near median its 10-year median of 21.61. Over the past 10 years, this metric has ranged from a low of 18.25 to a high of 27.51. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.57. Shanghai HeartCare Medical Technology's value of 21.01 is 10.8% below this industry median. Based on the distribution chart, Shanghai HeartCare Medical Technology ranks #205 out of 456 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's PE Ratio without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai HeartCare Medical Technology ranks #205 out of 456 companies for PE Ratio without NRI. This puts Shanghai HeartCare Medical Technology in the upper half of its industry. The industry median PE Ratio without NRI is 23.57. Shanghai HeartCare Medical Technology's value of 21.01 is 10.8% below this benchmark. Historically, Shanghai HeartCare Medical Technology's own PE Ratio without NRI has ranged from 18.25 to 27.51 over the past decade. While the company's 10-year median is 21.61 vs. the industry median of 23.57, Shanghai HeartCare Medical Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.57, based on 456 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai HeartCare Medical Technology's current PE Ratio without NRI of 21.01 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Shanghai HeartCare Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai HeartCare Medical Technology's current PE Ratio without NRI is 21.01, which is near median its own 10-year median of 21.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current PE Ratio without NRI is 21.01, which is near median its 10-year median of 21.61 and 10.8% below the Medical Devices & Instruments industry median of 23.57. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current PE Ratio without NRI is 21.01 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued.
The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80.
GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.
Key valuation signals for HKSE:06609:
PE Ratio without NRI: 21.01 (near median its 10-year median of 21.61)
GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
Industry Position: 10.8% below the Medical Devices & Instruments median (#205 of 456)
No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score
Get the complete analysis for HKSE:06609
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06609 has been successfully added to your 
